Abstract: Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R1, R2 and R3 is H, ORa, OCORa, OCO—ORa, alkyl, alkenyl, alkynyl, etc.; R3? is, CORa, COORa, CONRaRb, etc; each of R4 to R10 and R12 is alkyl, alkenyl or alkynyl; R11 is H, CORa, COORa, alkyl, alkenyl or alkynyl, or R11 and R12+N+C atoms to which they are attached may form a heterocyclic group; each of R13 and R14 is H, CORa, COORa, alkyl, alkenyl or alkynyl; each Ra and Rb is H, alkyl, alkenyl, alkynyl, etc.

Abstract: The solar tracker includes a pivoting assembly (2) having solar panels (3) fixed to a rotating shaft (1), a fixed structure with support elements (4, 5, 6) rotationally supporting the rotating shaft (1), a motor-reducer assembly (7) having an irreversible reducer (24) connected to the rotating shaft (1) at a motor connection point (12), and a torsional vibration damping device (8) having a moving member (9) rigidly connected to the rotating shaft (1) at a damper connection point (13) spaced apart from the motor connection point (12) and a stationary member (10) rigidly attached to the fixed structure. Both the moving member (9) and the stationary member (10) comprises elements capable to generate a magnetic field when a movement of the moving member (9) relative to the stationary member (10) occurs, resulting in a damping torque on the rotating shaft (1).

Abstract: In an embodiment, a photoinitiation apparatus includes: a set of illumination sources or elements configured for outputting optical energy; a body structure having a proximal body structure portion confining a proximal volume of explosive medium, an intermediate body structure portion confining an intermediate volume of explosive medium, and a distal body structure portion confining a distal volume of explosive medium, wherein the proximal volume of explosive medium is optically coupled to portions of the first volume of explosive medium, at least one of the proximal volume of explosive medium and the distal volume of explosive medium is a tertiary explosive medium, and (a) the body structure does not carry a primary explosive composition and does not carry a secondary explosive composition, and/or (b) each of the proximal, intermediate, and distal volumes of explosive media has an initiation sensitivity that is less than cyclotrimethylenetrinitramine (RDX) based explosive compositions.

Abstract: A method of extracting metals from polymetallic sulphide ores or concentrates comprising at least Cu, Zn, Pb and Ag, comprising a first step of atmospheric leaching in sulphate medium in the presence of recycled silver for extracting Cu and Zn and a second step of atmospheric leaching in chloride medium for extracting Pb and Ag.

Abstract: A demountable hitching device for towing by vehicles, by means of an angled arm (6, 6?) with a horizontal section (17) for its coupling and a vertical section ending in an upper ball (7, 7?), including a baseplate or support (8, 8?) wherefrom a rod emerges vertically (9) or horizontally (16) for its coupling to a bush (1, 1?) of a cubic shape and with one open side, inferiorly or frontally, respectively. The device features a locking slide (15), displaceable along the rod (9) emerging from the baseplate (8) and guided by a longitudinal channel. In an alternative version, the locking means consists of a pin constituted by a ring (21) which is adjustable to the rod (9?) of the baseplate (8?); for this purpose, the rod (9?) presents a flat side with transversal grooves (20), and in a diametrically opposite position, a longitudinal groove (25) to house a lug (24) projecting inwards from a lateral wall (23) of the pin.

Abstract: The present invention relates to a compound of general formula I and to the use thereof as a hapten. An object of the present invention is also a conjugate of said compound I with a carrier protein or fragment thereof, with a detectable labelling agent, or with a polymer or support, and to the use thereof for producing antibodies. Furthermore, the present invention also relates to a method for the detection and/or quantification of 1-hydroxyphenazine and/or pyocyanin using said antibodies and conjugates for the detection of infections caused by Pseudomonas aeruginosa.

Abstract: A protection application detects and removes unwanted applications. The protection application scans a client device for suspected unwanted applications. A security server provides an application rating for detected applications to the client device. The application rating is generated based on application retention data received from client devices indicating whether users of the clients choose to remove or retain the application when given the option. The application retention data may be weighed based on a categorization of the clients providing the application retention data into to clients expected to have different reliability levels. The security server can also provide a definition specifying all known components associated with a suspected unwanted application. Responsive to a selection to remove a suspected unwanted application, the protection application uninstalls all components of the application.

Abstract: The present invention provides an in vitro method for obtaining data useful for diagnosing a cardiomyopathy in a human subject, wherein the method comprises using, as an indicator, the expression levels, obtained from a biological sample isolated from the human subject, preferably a plasma sample, of one or more of the following miRNAs miR-721 and/or miR-155); and obtaining a result of the method by comparing the expression levels of said one or more miRNAs with a reference value or with the expression levels of a control, indicator of the absence of cardiomyopathy.

Abstract: A protection application detects and removes unwanted applications. The protection application scans a client device for suspected unwanted applications. A security server provides an application rating for detected applications to the client device. The application rating is generated based on application retention data received from client devices indicating whether users of the clients choose to remove or retain the application when given the option. The application retention data may be weighed based on a categorization of the clients providing the application retention data into to clients expected to have different reliability levels. The security server can also provide a definition specifying all known components associated with a suspected unwanted application. Responsive to a selection to remove a suspected unwanted application, the protection application uninstalls all components of the application.

Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.

Abstract: A protection application detects and removes unwanted applications. The protection application scans a client device for suspected unwanted applications. A security server provides an application rating for detected applications to the client device. The application rating is generated based on application retention data received from client devices indicating whether users of the clients choose to remove or retain the application when given the option. The application retention data may be weighed based on a categorization of the clients providing the application retention data into to clients expected to have different reliability levels. The security server can also provide a definition specifying all known components associated with a suspected unwanted application. Responsive to a selection to remove a suspected unwanted application, the protection application uninstalls all components of the application.

Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.

Abstract: The present invention is directed to novel pharmaceutically acceptable, addition salts of (S)-2-(1-(6-amino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phenyl-3,4-dihydropyrrolo[1,2-f][1,2,4]triazine-5-carbonitrile with sulfonic acid derivatives, in particular with methanesulfonic acid, naphthalene-2-sulfonic acid and para-toluenesulfonic acid, and pharmaceutically acceptable solvates thereof, and their use as Phosphoinositide 3-Kinase (PI3K) inhibitors.

Abstract: The present invention discloses the use of isolated short sequence motifs capable of directing or packaging regulatory nucleic acids, preferably RNAs, into extracellular vesicles, preferably exosomes. This mechanism is enhanced by the binding of hnRNP family proteins, which are sumoylated, to such nucleic acid. In this sense, sumoylated hnRNPs directs the loading of nucleic acids into EVs through recognition of specific short motifs disclosed in the present invention. Additionally, the present invention discloses recombinant nucleic acids comprising such sequence motifs, EVs in turn comprising these recombinant nucleic acids, as well as the compositions, preferably pharmaceutical compositions comprising either the recombinant nucleic acids or the EVs of the invention. The identification of such motifs is a useful tool for use in genetic engineering and gene therapy.

Abstract: Drug conjugates of formula [D-(X)b-(AA)w-(L)-]n-Ab wherein: D is a drug moiety having the following formula (I) or a pharmaceutically acceptable salt, ester, solvate, tautomer or stereoisomer thereof, wherein: A is selected from (II) and (III) R1, R2 and R3 is H, ORa, OCORa, OCO—ORa, alkyl, alkenyl, alkynyl, etc; R3? is, CORa, COORa, CONRaRb, etc; each of R4 to R10 and R12 is alkyl, alkenyl or alkynyl; R11 is H, CORa, COORa, alkyl, alkenyl or alkynyl, or R11 and R12+N+C atoms to which they are attached may form a heterocyclic group; each of R13 and R14 is H, CORa, COORa, alkyl, alkenyl or alkynyl; each Ra and Rb is H, alkyl, alkenyl, alkynyl, etc.

Abstract: The present invention relates to a compound of general formula I and to the use thereof as a hapten. An object of the present invention is also a conjugate of said compound I with a carrier protein or fragment thereof, with a detectable labelling agent, or with a polymer or support, and to the use thereof for producing antibodies. Furthermore, the present invention also relates to a method for the detection and/or quantification of 1-hydroxyphenazine and/or pyocyanin using said antibodies and conjugates for the detection of infections caused by Pseudomonas aeruginosa.

Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.

Abstract: A compound of general formula (I) wherein A, Y, R1, R2, R3, R4, R5, and R6 take various meaning or use in the treatment of cancer.

Abstract: A compound of general formula (I) wherein A, Y, W, R1, R2, R3, R4, R5, and R6 take various meanings for use in the treatment of cancer.